FY25 revenue guidance includes in-line products, potential new product launches, and royalty revenue from Evrysdi. Sees FY25 GAAP R&D and SG&A expenses $805M-$835M; non-GAAP R&D and SG&A expenses $730M-$760M, excluding estimated non-cash, stock-based compensation expense of $75M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics reports Q4 EPS (85c), consensus (65c)
- Is PTCT a Buy, Before Earnings?
- Hold Rating on PTC Therapeutics Amidst Mixed Outcomes for Vatiquinone in Friedreich’s Ataxia Treatment
- PTC announces FDA acceptance, priority review of NDA for vatiquinone
- PTC Therapeutics price target raised to $63 from $60 at RBC Capital